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Introduction 
It is estimated that 6.5% of adults aged 20-79 years 
have type 2 diabetes in South Africa. An age-adjusted 
prevalence of up to 13% has been described in urban 
populations.1 The effects of urbanisation, lack of exercise 
and unhealthy eating habits have been found to be 
important contributors to the rising prevalence of type 2 
diabetes, as well as obesity, in the country.1 
Type 2 diabetes is a progressive disease which may 
require intensification of therapy over time. Management 
includes a prudent diet, regular exercise and medicine to 
reduce blood glucose levels. Current pharmacological 
options in the management of type 2 diabetes include 
sulphonylureas, insulin, thiazolidinediones, a-glucosidase 
inhibitors and metformin. These treatment options, 
although highly effective in reducing blood glucose 
levels, may be associated with an increased risk of 
hypoglycaemia, as seen with sulphonylureas and insulin; 
weight gain, as noted with insulin, sulphonylureas and 
thiazolidinediones; and gastrointestinal intolerance, 
as observed with metformin. These unwanted adverse 
effects may act as barriers to optimal glycaemic control.2 
As a result, newer and safer treatment options for optimal 
glycaemic control are continuously being investigated 
and developed. The glucagon-like peptide 1 (GLP-1) 
agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are 
examples of such development. 
This article will focus on the DPP-4 inhibitors, also known 
as the “gliptins”, and their place in therapy in the 
management of type 2 diabetes. 
A closer look at dipeptidyl peptidase-4 inhibitors 
DPP-4 inhibitors are a new class of medicine that work 
to potentiate the effect of incretin hormones. Incretin 
hormones are secreted from the gastrointestinal tract 
(the enteroendocrine cells), into the bloodstream in 
response to food intake. The two most well-characterised 
incretin hormones are the GLP-1 and glucose-dependent 
insulinotopic polypeptide, also known as gastric inhibitory 
peptide (GIP). GLP-1, in particular, appears to be 
responsible for the majority of the incretin effects on the 
pancreatic .-cell function.2,3 
When blood glucose levels are elevated following a meal, 
GLP-1 is released from the gastrointestinal tract, and it: 
• Stimulates insulin secretion from the pancreatic b cells. 
• Reduces glucagon secretion from the pancreatic 
a cells. 
• Improves b-cell function. 
• Slows gastric emptying.2,3 
Circulating levels of GLP-1 are low in the fasting state, 
and rise quickly following a meal. However, GLP-1 has a 
very short half-life and is rapidly degraded by the enzyme, 
DPP-4.2-6 In an attempt to harness the beneficial effects 
of GLP-1, research has focused on interventions along 
the GLP-1 pathway. The result of this research has been 
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the development of GLP-1 agonists, e.g. exanetide and 
liraglutide, as well as the DPP-4 inhibitors. 
GLP-1 agonists have a protein-based structure, and 
although they have a longer half-life than endogenous 
GLP-1, they require parenteral administration as is the 
case with exenatide (Byetta®) and liraglutide (Victoza®). 
Both of these are available as pen devices.1,3,4,7
In contrast to this, DPP-4 inhibitors are smaller molecules 
that can be absorbed intact from the gastrointestinal 
tract, making oral administration possible.3 
Figure 1 is a schematic representation of the mechanism 
of action of DPP-4 inhibitors. 
Despite their common mechanism of action, the DPP-
4 inhibitors show marked differences in their chemical 
structure.2,4,6 This may explain some of the variance in the 
pharmacokinetic profiles of these products. 
Drug interaction profile 
In general, DPP-4 inhibitors do not interfere with 
cytochrome P450 (CYP) enzymes. They are neither 
inhibitors nor inducers. The exception is saxagliptin 
(Onglyza®), which is metabolised by the CYP3A4/5 isoform 
into a primary active metabolite.8,9 As a result, saxagliptin 
may require dosage adjustment if taken concurrently with 
CYP3A4/5 inhibitors, such as ketoconazole, itraconazole, 
indinavir, nelfinavir, ritonavir and saquinavir.1,8,10 
The absence of significant drug-drug interactions with this 
class of medicine can be explained by their favourable 
pharmacokinetic characteristics and their low plasma-
protein binding.4,8,10 
Safety profile 
DPP-4 inhibitors have been generally well-tolerated in 
short-term studies. Common reported adverse effects 
include nasopharyngitis (inflammation of the nasal 
passages), urinary tract infections, pancreatitis and 
headaches. Serious allergic reactions have been reported, 
including anaphylactic reactions, angioedema and 
exfoliative dermatological reactions.1-5 The incidence of 
hypoglycaemia is low, but may be increased when DPP-4 
inhibitors are used in combination with other antidiabetic 
agents. The DPP-4 inhibitors also appear to be less likely to 
be associated with weight gain. 
Since these products are fairly new on the market, long-
term, real-life experience with their use is needed to 
further confirm their safety profile. 
Available dipeptidyl peptidase-4 inhibitors 
Various DPP-4 inhibitors are at different stages of 
development and registration across the globe. These 
include sitagliptin, vildagliptin, alogliptin, saxagliptin and 
linagliptin. 
Sitagliptin was the first of the DPP-4 inhibitors to be 
approved by the US Food and Drug Administration in 
2006. This was followed by the approval of vildagliptin 
in February 2007. Saxagliptin (Onglyza®), vildagliptin 
(Galvus®) and sitagliptin (Januvia®) are currently available 
on the South African market.7,9,11-13 
Table I lists some of the internationally available DPP-4 
inhibitors. 
The place of dipeptidyl peptidase-4 inhibitors in 
therapy
DPP-4 inhibitors are effective as monotherapy, and also in 
combination with other oral antidiabetic agents. Plasma 
DPP-4 inhibition profiles are consistent with once-daily 
dosing for all members of this class, with the exception of 
Galvus® .2,8,10 
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DPP-4: dipeptidyl peptidase-4, GIT: gastrointestinal, GIP: gastric inhibitory peptide, GLP-1: glucagon-like peptide 1 
Figure 1: Schematic representation of the mechanism of action of dipeptidyl peptidase-4 inhibitors
Review: Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
76 2015 Volume 20 No 1JEMDSA
DPP-4 inhibitors are contraindicated when there is: 
• Compelling indication for insulin therapy. 
• A history of a serious hypersensitivity reaction to DPP-4 
inhibitors. 
• A patient with a history of acute pancreatitis, chronic 
or recurring pancreatitis, or pancreatic cancer.1
Conclusion 
The development of DPP-4 inhibitors, which potentiate 
the incretin hormones by inhibiting the enzyme that is 
responsible for their degradation, has recently emerged 
as an approach that appears to be promising for the 
treatment of type 2 diabetes. 
Although these agents have modest efficacy [they 
reduce haemoglobin A1c(HbA1c) by 0.5-1.1% compared to 
placebo], they represent an important class of compounds 
that provide an alternative to other traditional therapies 
that are used in the management of type 2 diabetes.1 
While they do not appear to lower glucose to a greater 
extent than existing therapies, when used alone, they offer 
the potential advantage of a low risk of hypoglycaemia 
and weight gain. As there is a low risk of hypoglycaemia 
developing with their use, they may be advantageous in 
patients who are close to achieving their target HbA1c, 
but who continually experience elevated glucose levels 
following a meal. 
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5 mg once daily 50 mg twice daily 
(once daily when 
used in combination 
with sulphonylureas)
100 mg once daily 5 mg once daily 25 mg once daily
Indication Adjunct to diet and 
exercise in adults with 
type 2 diabetes, either 
as monotherapy or 
in combination with 
other antidiabetic 
agents
Adjunct to diet and 
exercise in adults with 
type 2 diabetes, either 
as monotherapy or 
in combination with 
other antidiabetic 
agents
Adjunct to diet and 
exercise in adults 
with type 2 diabetes, 
either as onotherapy 
or in combination 
with metformin or a 
thiazolidinedione
Not registered in South 
Africa. (Approved by 
the FDA)
Not registered in South 
Africa. (Approved by 
the FDA)
Selectivity for DPP-4 Moderate Moderate High Moderate Moderate















Use in renal 
impairment
Dosage adjustment 
is required in patients 
with moderate 
or severe renal 
impairment
Contraindicated 
in patients with 










is required in patients 
with moderate 
to severe renal 
impairment
Use in hepatic 
impairment
Contraindicated 
in patients with 
moderate to severe 
disease
Contraindicated Contraindicated in 






required in patients 





interaction with strong 
CYP3A4/5 inhibitors 
e.g. ketoconazole
Low Low Low Low
*Vildagliptin and sitagliptin are also available in combination with metformin as Galvus Met® and Janumet®, respectively, indicated as an adjunct to diet and exercise in patients 
with type 2 diabetes who are already stabilised on the combination of DPP-4 inhibitors and metformin.12 
CYP3A4/5: cytochrome 3A4/5, DDP-4: dipeptidyl peptidase-4, FDA: US Food and Drug Administration, HbA1c: haemoglobin A1c 
